A patient on amiodarone reports a dry cough. Which statement best describes the recommended action by a pharmacist?

• A. Reassure the patient and continue therapy
• B. Arrange a routine follow-up in 1-2 weeks
• C. Stop amiodarone and switch immediately
• D. Refer the patient to the prescriber for urgent review

Answer: (D)

Recognizing potentially serious adverse effects of amiodarone and the need for urgent clinical evaluation. A dry cough in someone taking amiodarone can be an early sign of amiodarone-induced pulmonary toxicity, which can progress rapidly and become life-threatening if not assessed promptly. Because this possibility requires timely medical investigation and potential adjustment of therapy, the most appropriate action for a pharmacist is to refer the patient to the prescriber for urgent review. This ensures the clinician can evaluate the risk, perform appropriate investigations (such as imaging and respiratory assessment), and decide whether to discontinue or modify amiodarone under medical supervision. Reassurance or a routine follow-up could delay necessary care, and stopping the drug without prescriber input could jeopardize the patient's cardiac rhythm management. In the meantime, document symptoms, assess severity, and advise seeking urgent care if dyspnea or chest symptoms worsen.